Navigation Links
Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
Date:7/30/2008

MARKHAM, ON, and OSAKA, Japan, July 30 /PRNewswire/ - Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S. and Asia, including Japan, to develop and commercialize CTA018, Cytochroma's novel vitamin D analog. CTA018 is entering Phase II development in Canada for the treatment of secondary hyperparathyroidism ("SHPT") in patients with chronic kidney disease ("CKD"). The agreement also grants MTPC access to certain follow-on compounds to CTA018 for the same territories, with Cytochroma retaining all rights to CTA018 and these follow-on compounds in all regions outside the U.S. and Asia.

Cytochroma's President and CEO, Charles W. Bishop, PhD, stated, "Mitsubishi Tanabe is a world-class company, which will provide Cytochroma with significant resources and pharmaceutical know-how, thereby facilitating the development and commercialization of CTA018 in the U.S. and Asia. The formation of this partnership is a landmark event for Cytochroma and represents an important validation of our novel approach to treating secondary hyperparathyroidism in CKD patients."

MTPC's President and Representative Director, Natsuki Hayama, stated, "I am excited with this synergistic partnership that combines the unique strengths of Cytochroma, a North American-based specialty pharmaceutical company, with Mitsubishi Tanabe, a Japan-based global pharmaceutical company. Cytochroma's management team has an extensive and successful track record in developing and commercializing products for CKD patients in North America. A partnership with Cytochroma not only enhances Mitsubishi Tanabe's product pipeline in the U.S. and Asia, but also enables us to access Cytochroma's valuable expertise for the development of our own commercialization platform in the U.S."

Under the terms of the agreement, Cytochroma has granted MTPC an exclusive
'/>"/>

SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Cytochroma Closes $45 Million Series C Financing
5. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
9. Healionics Corporation Announces Partnership to Develop and Distribute STARcuff(TM)
10. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
11. VIA Pharmaceuticals Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Informations Therapeutic Area Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015  Scientists from Cleave Biosciences will be participating ... at the American Association for Cancer Research Annual Meeting ... Sunday, April 19, 2015 from 3:15pm to 5:15pm ET. ... will present new in vivo and mechanism of action ... p97, a critical enzyme that controls various aspects of ...
(Date:4/16/2015)... LAUSANNE , Switzerland ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ ... prescription drugs that target unmet medical needs ... that preclinical data on the investigational compounds ... inhibitor) will be presented at the 2015 ...
(Date:4/16/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... DCVax® personalized immune therapies for cancer, announced today ... Cancer Immunotherapy Index (LCINDX), a professional index recently ... field within the biotechnology space.  ... companies" in the immunotherapy space, including 6 big ...
(Date:4/16/2015)... 2015 CCI Global Channel Management, the ... planning management software for major tech and telecom vendors, ... survey of channel vendor programs in software, hardware, and ... How the top IT vendors in each segment ... coming year. , Assessment of the state ...
Breaking Biology Technology:Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3
... what could be a shot in the arm for ... enhancing and controlling the growth of T cells in ... one of the therapy,s drawbacks. The engineers altered ... in which researchers can build new functions into cells ...
... TRIANGLE PARK, N.C. , April 26 Talecris Biotherapeutics Holdings ... results on April 28, 2010 , after the stock market closes ... on April 29, 2010 . , ... Investors and analysts may participate via phone by ...
... Volcano Corporation (Nasdaq: VOLC ), a leading developer and manufacturer ... treatment of coronary and peripheral vascular disease, today announced that it will ... Monday, May 3 . , ... The company will hold a conference call to discuss its financial ...
Cached Biology Technology:New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher 2New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher 3Talecris Biotherapeutics to Report First Quarter 2010 Financial Results 2Volcano Corporation Schedules First Quarter Conference Call, Webcast 2
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... the "Global Gesture Recognition Market in Automotive Sector ... analysts forecast the Global Gesture Recognition market in Automotive ... the period 2013-2018. Gesture recognition is the ... different gestures of an individual. Gesture recognition technology can ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... U.S. Department of Homeland,Security (DHS) announced today ... international visitors arriving at New York,s John ... part of the department,s,upgrade from two- to ... travel by more accurately and efficiently,establishing and ...
... that guide one of the two groups of pathogenic ... defense against the world. The work, they said, ... bacteria, like E. coli and salmonella, that would destroy ... protective coating. "A long-term goal is to find ...
... gene is integral to both fungal invasion of corn and ... lead to ways to control the pathogen and the poison. ... found that it is vital to the process of the ... when the scientists disabled the gene. At certain levels, ...
Cached Biology News:DHS Begins Collecting 10 Fingerprints From International Visitors at New York's John F. Kennedy International Airport 2Ant guts could pave the way for better drugs 2Defining gene's role may lead to prevention of dangerous corn toxin 2Defining gene's role may lead to prevention of dangerous corn toxin 3
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
... 1 kit. Facilitates the simple, phenol-free extraction ... hard tissue requiring proteinase K digestion.Each kit ... from 50 preparations of up to 25 ... & Purification, Purification and Amplification of Genomic ...
Request Info...
Ultra-sensitive, non-radioactive measurement of COX-I and COX-II activity...
Biology Products: